Kyverna Therapeutics

kyvernatx.com

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, kyv-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label phase 1/2 trials in the united states and germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (car) t-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in b cell-driven autoimmune diseases.